Lenvima (Lenvatinib Mesylate) Patent Expiration, LOE Window & CMS Spending
Lenvima (Lenvatinib Mesylate) by Eisai: FDA Orange Book core substance LOE 2036-02-26 (last listed 2038-11-15), 0 AB generics, $1.01B 2024 CMS Part D & Medicaid spend, and 48 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Eisai |
| FDA Application & Pathway | N206947 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2036-02-26 |
| Last Listed Patent or Exclusivity Date | 2038-11-15 |
| Orange Book Patents (*PED Extensions) | 20 patents (10 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $1.01B |
| 2024 Medicare Part D Spend | $875.6M |
| 2024 Medicaid Spend | $135.0M |
| Reported Wholesale Price Change (CA SB 17) | 48 WAC filings (max 23.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.